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Introduction: Aedes (Stegomyia) aegypti is the vector for dengue, chikungunya, and Zika arboviruses. 
Bti-CECIF is a bioinsecticide designed and developed in the form of a solid tablet for the control of this 
vector. It contains Bacillus thuringiensis var. israelensis (Bti) serotype H-14.
Objective: To evaluate under semi-field and field conditions the efficacy and residual activity of Bti-
CECIF tablets on Aedes aegypti larvae in two Colombian municipalities.
Materials and methods: We tested under semi-field conditions in plastic tanks (Rotoplast™) four 
different Bti doses (0.13, 0.40, 0.66 and 0.93 mg/L) in the municipality of Apartadó, department of 
Antioquia, to assess Bti-CECIF efficacy (percentage of reduction of larval density) and the residual 
activity in water tanks containing A. aegypti third-instar larvae. The efficacy and residuality of the most 
lethal dose were subsequently evaluated under field conditions in cement tanks in the municipality of 
San Carlos, department of Córdoba.
Results: Under semi-field conditions, the highest tested dose exhibited the greatest residual activity 
(15 days) after which larval mortality was 80%. Under field conditions, the highest tested Bti-CECIF 
doses showed 100% mortality and exhibited a residual activity of seven days in 90% of the tanks.
Conclusion: Bti-CECIF tablets effectively controlled A. aegypti larvae under field conditions for up to 
seven days post-treatment.
Key words: Aedes; Bacillus thuringiensis; disease vectors; dengue; chikungunya virus; Zika virus; 
Colombia.
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Nuevas tabletas larvicidas de Bacillus thuringiensis var. israelensis: evaluación del efecto 
larvicida sobre Aedes aegypti (Diptera: Culicidae) en Colombia
Introducción. Aedes (Stegomyia) aegypti es el vector de los arbovirus del dengue, el chikungunya y el 
Zika. Para el control de este vector, se diseñó y desarrolló un bioinsecticida en presentación de tableta 
sólida, el Bti-CECIF, que contiene Bacillus thuringiensis var. israelensis (Bti) de serotipo H-14.
Objetivo. Evaluar en condiciones de ‘semicampo’ y de campo, la eficacia y la actividad residual de las 
tabletas de Bti-CECIF en larvas de A. aegypti en dos municipios colombianos.
Materiales y métodos. En el municipio de Apartadó, departamento de Antioquia, se probaron bajo 
condiciones de ‘semicampo’ en tanques de plástico de 250 l (Rotoplast™) cuatro dosis diferentes de 
Bti (0,13, 0,40, 0,66 y 0,93 mg/l) para evaluar la eficacia del Bti-CECIF (porcentaje de reducción de la 
densidad larvaria) y la actividad residual en tanques de agua que contenían larvas de tercer estadio de A. 
aegypti. La eficacia y el efecto residual de la dosis más letal fueron posteriormente evaluadas en tanques 
de cemento bajo condiciones de campo en el municipio de San Carlos, departamento de Córdoba.
Resultados. Bajo condiciones de ‘semicampo’, la mayor dosis probada exhibió la mayor actividad 
residual (15 días), después de lo cual la mortalidad de las larvas fue de 80 %. Bajo condiciones 
de campo, la máxima dosis probada de Bti-CECIF mostró una mortalidad de 100 % y exhibió una 
actividad residual de siete días en el 90 % de los tanques.
Conclusión. Las tabletas Bti-CECIF controlaron eficazmente A. aegypti en condiciones de campo 
durante siete días a partir de su aplicación.
Palabras clave: Aedes, Bacillus thuringiensis; vectores de enfermedades; dengue; virus chikungunya; 
virus Zika; Colombia.
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Vector-borne diseases account for over 17% of 
all infectious diseases and are a significant con-
tributing cause of human deaths worldwide (1). 
Dengue, chikungunya, and Zika arboviruses 
are transmitted by the vector Aedes (Stegomyia) 
aegypti and they represent a permanent global 
health threat with social and economic impacts (2).
Currently, dengue is the most frequent arboviral 
disease diagnosed in tropical and sub-tropical coun-
tries. Recently, it has been estimated that there are 
390 million dengue infections per year, of which 96 
million manifests with clinically apparent disease 
(3). In the Americas, a total of 580,395 cases of 
dengue were reported in 2017, of which 1,940 cases 
were of severe dengue and 306 cases were deaths 
(4). In Colombia, the estimated average of dengue 
infections per year between 2013 and 2017 was 
91,454 cases, of which 1,728 were severe dengue, 
and 111 were deaths (Sivigila, Instituto Nacional 
de Salud) (5-9). In 2016, the reported incidence of 
dengue was 101,016 cases (99.1%) and 899 cases 
of severe dengue (0.9%) (8). Additionally, 26,279 
cases of dengue were reported in 2017 (9).
Furthermore, the recent introduction of Zika 
and chikungunya arboviruses in the Colombian 
Caribbean region expanded throughout the entire 
country. In 2014 and 2015 a total of 106,763 
and 360,570 chikungunya cases were reported, 
respectively (10), while up to the epidemiological 
week 52 of 2016, 19,435 cases of chikungunya virus 
were reported (11). Additionally, 106,660 cases of 
Zika virus were reported from the epidemiological 
week 32 of 2015 to the epidemiological week 52 
of 2016 (12).
Dengue, chikungunya, and Zika arboviruses are 
a public health concern as they may lead to epi-
demics in large cities and metropolitan areas 
(13). For this reason, the main course of action 
to reduce transmission of these diseases is 
based on the control of the vector A. aegypti with 
insecticide aspersion, as well as larvicide control 
and management means to reduce breeding sites. 
The main vector-control strategy focuses today 
on insecticide aspersion, which can be expensive 
and difficult to maintain. For that reason, the World 
Health Organization (WHO) has proposed the use 
of biolarvicides such as Bacillus thuringiensis var. 
israelensis (Bti) for the prevention and control of 
arboviral diseases (document CD55/16) depending 
on the particular conditions of each country (14).
Since 1950, one of the most successful strategies 
for controlling this vector has been the use of Bacillus 
thuringiensis var. israelensis (Bti) bacteria, whose 
biolarvicidal effect is specific for controlling species 
of the Culicidae family, including A. aegypti (15-18). 
In Colombia, Bti is available and commercialized 
as “VectoBac 200G™”, and contains Bti serotype 
H-14 as the bioactive ingredient. Once ingested by 
larvae, peptide toxins known as delta-endotoxins 
are activated. Delta-endotoxins are pore-forming 
toxins that bind to the gut epithelium and lyse 
cellular membranes, and ultimately lead to the 
death of A. aegypti larvae (15-18).
However, this commercially available product 
presents several drawbacks, including the fact 
that it is not locally produced and must, therefore, 
be imported, increasing its cost significantly. 
Furthermore, application volumes of this granular 
formulation vary and to properly dose it, a special 
equipment must be used to weigh the amount 
of required product. Additionally, the product is 
susceptible to physicochemical instability after 
package opening and given that VectoBac 200G™ 
is commercialized by a single company, its acces-
sibility may be occasionally restricted.
In order to overcome these issues, at the Centro de 
la Ciencia y la Investigación Farmacéutica, CECIF, 
we designed and developed a bioinsecticide in a 
solid tablet presentation that contains Bti serotype 
H-14, the same bioactive ingredient of VectoBac 
200G™, which will be referred to as Bti-CECIF in 
the present article.
In this study, we assessed the efficacy and residual 
activity of Bti-CECIF tablets on A. aegypti larvae 
under semi-field conditions in the municipality of 
Apartadó (department of Antioquia), as well as 
under field conditions in two neighborhoods of the 
municipality of San Carlos (department of Córdoba).
Materials and methods
Tablets
Throughout the product design and development 
process, efficacy trials were run at laboratory scale 
reporting the mortality percentage according to Bti 
serotype H-14 concentration. Additionally, differ-
ent production processes were tested in order to 
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identify the appropriate method to compress this 
type of raw material, which were then validated 
by physicochemical and microbiological methods 
(unpublished data). 
Once we identified a formulation that met the 
requirements of the accelerated pre-stability test-
ing, we performed toxicity studies including acute 
oral toxicity, acute dermal toxicity and toxicity by 
inhalation, dermal sensitivity, dermal irritation, and 
ocular irritation (unpublished data). These tests 
are required to apply for the toxicological technical 
report issued by the Instituto Nacional de Salud.
Semi-field bioassay
Mosquitoes. We used third instar A. aegypti 
larvae obtained from an established colony at the 
Instituto Colombiano de Medicina Tropical, ICMT, 
located in Sabaneta, Antioquia. This colony was 
generated from eggs provided by the Grupo de 
Entomología Médica at the Facultad de Medicina 
of the Universidad de Antioquia. The larvae were 
bred in plastic trays and fed fish food. The adult 
mosquitoes were fed with 10% sugar solution 
and mouse blood every third day to obtain their 
eggs. The insectary was maintained at an average 
temperature of 27°C and a relative humidity of 
60%, with a photoperiod of 12 h, according to the 
Gerberg methodology (19). 
The colony was composed of field specimens 
collected in Medellín, where insecticide suscep-
tibility has been evaluated in several populations 
using the standard WHO susceptibility test (20). The 
following insecticides have been tested: organo-
phosphates (malathion, fenitrothion, temephos), 
and pyrethroids (deltamethrin, permethrin, lambda-
cyhalothrin). Mosquitos were susceptible to mala-
thion (>98% mortality), while there was some risk of 
resistance to other insecticides (80-95% mortality) 
(21). In Medellín, Bti biolarvicide is not regularly 
applied (personal communication, Dr. Guillermo Rúa).
Bti products. For field and semi-field experiments, 
we used 600 mg Bti-CECIF tablets containing 
1.33% active ingredient per tablet and 5,240 ITU/
mg. As a negative control, we used 600 mg tablets 
without Bti.
Study site. We conducted the semi-field experi-
ments at the ICMT headquarters located in the mu-
nicipality of Apartadó (7º53’28.4’’ N and 76º37.69’’ 
W; elevation 49 masl) following WHO guidelines 
for laboratory and field testing of mosquito larvi-
cides (20).
Experimental protocol for semi-field bioassay. We 
evaluated Bti-CECIF tablets efficacy and residual 
activity at the following doses: 0.13, 0.40, 0.66, 
and 0.93 mg/L. CECIF tablets lacking Bti (0 mg/L) 
were used as negative control. We used 20 250-
L plastic tanks (Rotoplast™) placed in the shade. 
The tanks were randomly labeled (four tanks per 
treatment) and filled with 180 L of aqueduct water. 
We added single batches of 100 laboratory-bred A. 
aegypti third instar larvae plus 1 g of fish to each 
tank and after 2 to 3 hours we administered the 
corresponding Bti-CECIF dose. We placed the 
tablets directly into the water without agitation. We 
registered larvae mortality daily and removed dead 
larvae from the tanks. Water pH and temperature 
were recorded throughout the bioassay.
During the experiment, tanks were kept under roof, 
in the shade, and covered with nets in order to 
avoid waste disposal, mosquitos laying eggs, or the 
invasion of predator macroinvertebrates, as well as 
to prevent the escape of adult mosquitos. Water 
lost by evaporation was replaced once a week.
Once all larvae had either died or hatched, we 
assessed residual activity in those same tanks with-
out adding any new tablets. To this end, each tank 
received a new batch of 50 A. aegypti third instar 
larvae on day 4. After 24 hours, larvae mortality 
was registered and followed daily. Again, once all 
larvae had either died or hatched, a second batch 
of 50 A. aegypti third instar larvae was added to 
each tank on day 10. This process was repeated 
on days 19 and 31 until no significant difference 
in residual activity was detected in larvae mortality 
between tanks treated with the highest dose of Bti-
CECIF and the negative control (20). 
Efficacy was assessed through percent reduction 
of larval density (% RLD) during the first week of 
evaluation while residual activity was assessed 
by measuring the duration of larvicide effect on 
a new batch of third instar larvae. The period 
of residual activity was defined as the day until 
which the % RLD was greater or equal to 80%. 
For this purpose, larval mortality was calculated at 
several time points post-treatment as follows: e1: 
mortality after one day of exposure to treatment 
(day 1, 5, 11, 20, and 32); e2: mortality after two 
days of exposure to treatment (day 2, 6, 12, 21, 
and 33), and so on, up to e4. These mortality data 
(e1 through e4) were adjusted to probit models in 
order to establish whether there was a relation-
ship between mortality and the Bti-CECIF dose 
and between mortality and days post-treatment 
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for each of the Bti-CECIF doses tested, with the 
exception of the negative control in which no 
mortality was observed.
Statistical analysis. Data were tabulated in Micro-
soft Excel™ spreadsheet and statistical analysis 
was performed using Statgraphics Centurion 
XVI™, version 16.1.02 software. Following WHO 
recommendations (20), the post-treatment % 
RLD was calculated with the following formula: 
%RLD = ( C-TC )×100, where C is the percentage 
survival in control tanks and T is the percentage 
survival in treated tanks during the same time 
period. However, given that the percentage sur-
vival in control tanks was of 100% in this study, the 
% RLD was calculated directly, i. e., 100-T.
Field bioassay
Study site. The field study was performed in two 
neighborhoods of the municipality of San Carlos 
(El Carmen and Porvenir), Córdoba (8º48’02” N and 
75º42’08” W; elevation 25 masl) with an average 
temperature of 28°C. San Carlos has an urban 
population of 5,123 inhabitants (22), and is located 
36 km from the capital city, Montería.
During the last trimester of 2014, San Carlos 
presented high infestation levels of immature A. 
aegypti (larvae and pupae): House index (HI): 
22%; container index (CI): 4%, and Breteau index 
(BI): 25%. It was also reported that 63% of positive 
breeding sites containing immature vector were 
low tanks (Secretaría de Salud de Córdoba, 2014). 
We selected two neighborhoods in San Carlos, El 
Carmen and Porvenir, because they presented the 
highest infestation levels of immature populations 
of A. aegypti in the municipality.
Before initiating the study, we explained the goals 
of the project to the head of each participating 
household, and upon approval, they signed an 
informed consent form. The Ethics Committee of 
the ICMT approved this study (Act 54, February 
27, 2015). This field study was performed following 
WHO guidelines for laboratory and field testing of 
mosquito larvicides (20). 
Experimental protocol for the field bioassay. In the 
selected neighborhoods, tanks naturally infested 
with A. aegypti larvae were identified and used 
to test the effectiveness and residual activity of 
the Bti-CECIF tablets (0.93 mg/L). A total of 21 
randomly selected tanks were treated with Bti-
CECIF tablets; as a negative control five randomly 
selected tanks were treated with tablets without 
Bti and as a positive control other five randomly 
selected tanks were treated with VectoBac 200G™ 
at a dose of 5 mg/L.
At the beginning of the experiment, we recorded 
data of larvae and pupae density at day 1 and day 
3 pre-treatment. In order to assess the density of 
immature instars, we analyzed 20 spoonful samples 
taken with a 300 mL ladle tied to a long cable (~1 
meter) that facilitated its handling. We measured 
the total sample volume in a graduated cylinder 
and calculated the total volume of the tank using 
its diameter and height. The number of Bti-CECIF 
tablets per tank was calculated based on the total 
tank volume regardless of the total amount of water 
contained in it at the time of treatment. Because of 
this, some of the tanks had an initial concentration 
of Bti-CECIF greater than 0.93 mg/L. 
Once we administered the treatment, larval density 
(all instars) was assessed every 24 h for three days. 
After the third day, we measured it three times per 
week for four weeks to assess the residual activity.
The water content of tanks varied with water con-
sumption and exchange (rain or aqueduct), leading 
to changes in bioactive ingredient concentration 
over time. At each time point, we estimated the 
bioactive ingredient concentration using the water 
volume registered for the day it was being measured 
and the number of tablets initially added to the 
tank (initial concentration of 0.93 mg/L assuming 
maximum volume capacity). Throughout the assay, 
we recorded water pH, changes in water level, and 
water temperature data and we registered as well 
the environmental temperature and the relative 
humidity for the municipality of San Carlos. 
Statistical analysis. Collected data was tabulated 
in a Microsoft Excel™ spreadsheet and the statis-
tical analysis was performed using Statgraphics 
Centurion XVI™, version 16.1.02 software.
Following WHO recommendations (20), we cal-
culated the post-treatment percentage reduction of 
larval density (% RLD) based on the Mulla formula 
(1971) (23): %RLD=100 - (C1T1 ) × (
C2
T2
)×100, where C1 
is the number of larvae in instars I, II, III, and IV 
in negative control tanks before administering 
the Bti-CECIF tablets; C2 is the number of larvae 
in instars I, II, III, and IV in negative control tanks 
after administering the Bti-CECIF tablets; T1 is the 
number of larvae in instars I, II, III, and IV in Bti-
CECIF treated tanks before administering the Bti-
CECIF tablets, and T2 is the number of larvae in 
instars I, II, III, and IV in Bti-CECIF treated tanks 
after administering the Bti-CECIF tablets. An 80% 
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RLD was defined as the cutoff, so Bti residual activity 
was considered to last until the day in which % RLD 
was greater or equal to 80%. A logistic regression 
model was adjusted for efficacy as a function of 
the number of days post-treatment with Bti-CECIF 
tablets. For this model, tanks with residual activity 
≥80% were coded as one (1), and those tanks 
in which there was no longer Bti residual activity 
(% RLD<80 %) were coded as zero (0).
Time-course analysis of Bti-CECIF tablet concen-
tration. In order to estimate the change in the 
bioactive ingredient concentration produced by 
water consumption and exchange, we assumed 
a constant dilution rate and used an exponential 
model to estimate the dilution rate for each of the 
tanks: Concentration = e-κ×dpt,  where κ is the dilution 
rate and dpt is the number of days post-treatment 
with Bti-CECIF tablets. High κ values indicate a fast 
dilution, while low κ values indicate a slow dilution.
Bti-CECIF residual activity between groups was 
compared by a variance analysis in which we 
defined the response variable as the last day at 
which treatment remained effective (% RLD≥80%) 
and subjected it to square root transformation prior 
to analysis.
Participants knowledge survey. Upon completion 
of the bioassay, a brief questionnaire was admin-
istered to the heads of the households participating 
in the study. Twenty-one structured surveys were 
administered by the two team members who had 
been assessing tablets efficacy (a biologist and a 
field assistant), including only the sampling units 
which would be assigned to the Bti-CEFIF treatment. 
We used the data-collection instrument previously 
described by Ocampo, et al. (24), after adapting it 
to the municipality context and the purpose of our 
study. The survey consists of 19 questions that 
assess participants knowledge regarding the vector 
and the use of Bti-CECIF tablets.
Results
Semi-field bioassay in Apartadó
During the experiment, the average temperature 
in Apartadó was 27.6°C ± 0.58 and the relative 
humidity, 92.6% ± 2.9. The tank water temperature 
ranged between 23.2 °C and 29.4 °C (average of 
27.3 °C ± 0.72). The tank water pH ranged between 
7.45 and 8.99 (average of 8.31 ± 0.29).
Bti-CECIF tablets efficacy assessment
Based on day 1 larval mortality data (table 1), a 
probit model was adjusted for Bti dose-dependent 
mortality. Using inverse prediction, we predicted 
a dose of 0.24 mg/L to achieve 80% mortality 
24 h post-treatment (figure 1). The dose of 0.93 
mg/L exhibited greater efficacy than the other Bti-
CECIF tested dosages. As expected, there was no 
mortality in tanks treated with tablets without Bti 
(negative control) (table 1).
Residual activity assessment
In order to evaluate the residual activity of Bti-CECIF 
tablets on A. aegypti larvae throughout the 40 days 
of the experiment, a probit model was adjusted for 
each of the doses with a function of time of expo-
sure. Mortality rates for each of the doses are shown 
in figure 2. No mortality was observed for negative 
controls (data not shown). During the entire dura-
tion of the experiment, the residual activity of the 
0.66 and 0.93 mg/L doses was greater than that of 
all the other tested Bti doses. 
For each of the tested doses, a probit model 
was adjusted for mortality as a function of post-
treatment days. To this end, inverse predictions 
were obtained from the day at which 80 % mortality 
was expected considering the different exposure 
days (e1, e2, e3, and e4) (figure 3).
Table 1. Mortality rate of Aedes aegypti stage III larvae treated 
with different doses of Bti-CECIF tablets
Dose 
(mg/L)
Number of 
Bti tablets
(180 L water)
Mortality (%)
Day 1 Day 2 Day 3 Day 4
0.13   3 78.7 10.2 5.5 5.5
0.40   9 97.7   1.5 0.7 0
0.66 15 99.7   0.2 0 0
0.93 21 98.7   0.5 0.7 0
Control    3* 0 0 0 0
*Tablets without Bti
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Figure 1. Probit model: Bti dose-dependent Aedes aegypti 
stage III larvae mortality in 180 L water tanks under semi-field 
conditions. Gray lines represent 95% confidence intervals.
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The doses exhibiting greater residual activity 
were 0.66 mg/L and 0.93 mg/L. For the latter, we 
estimated that an 80 % mortality rate would be 
reached 15 days post-treatment after larvae were 
exposed for four days. Although there was no sig-
nificant difference in the effect of these two doses, 
we chose the highest taking into consideration that 
in the field there would be water exchange and, 
thus, a decrease of the concentration of the active 
ingredient. For this reason, we selected the 0.93 
mg/L dose for the test under field conditions in San 
Carlos, Córdoba.
Field bioassay in San Carlos
During the experiment, the average temperature 
in San Carlos was 27.6°C ± 1.93 and the relative 
humidity, 72.6 % ± 4.1. The tank water temper-
ature ranged between 26°C and 35.1°C (average 
of 30.5 °C ± 1.83). The tank water pH ranged 
between 7.12 and 9.98 (average of 7.96 ± 0.51). 
All of the evaluated tanks were naturally infested 
with A. aegypti larvae and pupae.
Aedes aegypti percentage of larval density 
reduction in tanks treated with Bti-CECIF tablets
Based on the observed RLD percentages during 
the 34 days after administering the Bti-CECIF 
tablets at a dose of 0.93 mg/L, a logistic model for 
efficacy (% RLD≥80%) was adjusted to the number 
of days post-treatment (p<0.0001). The day for 
which a given probability of efficacy is expected 
can be estimated by performing an inverse predic-
tion. Thus, if we have that there is a 0.9 probability 
that the product maintains its efficacy until around 
the seventh day, this means that seven days post-
treatment approximately 90% of the tanks treated 
with Bti-CECIF tablets at a 0.93 mg/L dose would 
be expected to maintain a % RLD≥80% (figure 4).
Time-course analysis of Bti-CECIF tablet 
concentration
Figure 5 shows the observed change in concentra-
tion as a function of the number of post-treatment 
days during the bioassay for each tank. The differ-
ences among tanks corresponded to the variation 
due to water consumption and exchange patterns.
For each of the tanks, we used the following 
exponential model to establish the progression 
of concentration/dilution over time: Concentration 
= e-κ×t. We defined two groups of tanks: 1) Tanks 
exhibiting below-average dilution rates (κ<0.094), 
and 2) tanks exhibiting above-average dilution 
rates (κ>0.094). We did not find a statically signifi-
cant effect of the dilution rate on product efficacy 
(F=0.128; error df=18; p=0.725).
The residual activity was not significantly different 
between Bti-CECIF tablets and VectoBac 200G™ 
(F=0.009; error df=24; p=0.926).
Participants knowledge survey
Participants age was 43 years old and younger. 
Regarding knowledge about dengue transmission, 
most participants (90%) were aware that chikun-
gunya and dengue viruses are transmitted by 
mosquito bites. The majority of them (81%) also 
indicated that this mosquito breeds in water tanks 
and less than a third of participants (28%) knew 
that washing water tanks was a strategy to avoid 
mosquito reproduction. All of the participants (100%) 
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Figure 2. Expected larval mortality based on a probit model 
using four doses of Bti-CECIF tablets on stage III larvae of 
Aedes aegypti in 180 L water tanks under semi-field conditions
Figure 3. Mortality of 80% was achieved using four doses of 
Bti-CECIF tablets on stage III larvae of Aedes aegypti in 180 L 
water tanks under semi-field conditions. Days required to reach 
80% mortality and days of exposure are graphed for the four 
different Bti-CECIF tablet doses.
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indicated that they used aqueduct water stored in 
cement tanks. About half (48%) of them stored the 
water for one to three days, 38% for four to seven 
days, and 14% for more than one week. Regarding 
tank washing, 95% of the participants said the 
washed their tanks, and 30% of these did so every 
two days, 45% on a weekly basis, and 25% every 
two weeks. Regarding the bioassay, 95% of the 
participants acknowledged that the administered 
tablets were efficient in killing mosquito larvae and 
that they had reduced their number. However, 62% 
of the responders indicated that the number of 
mosquitos (A. aegypti and Culex spp.) inside the 
house had not reduced. 
Discussion
We report the efficacy and residual activity of Bti-
CECIF tablets on A. aegypti larvae under semi-field 
and field experimental conditions in two Colombian 
municipalities. The use of Bti as a control strategy 
for A. aegypti larvae has been previously reported 
using different formulation and doses, particularly 
in countries where temephos resistance has been 
reported in A. aegypti populations (25,26). 
In Colombia, the use of Bti is a complementary 
alternative for vector control in potable water 
tanks and other breeding sites (27-29), especially 
in regions where larvae have become resistant to 
temephos (27,29,30). The production and com-
mercialization of a pharmaceutical formulation of 
Bti tablets developed and produced in Colombia 
would significantly reduce costs and increase 
product availability, leading to successful A. aegypti 
vector-control. Furthermore, this would contribute 
to proper dosage, as only the administration of 
a given number of tablets according to the tank 
volume would be required, as well as to product 
stability by packaging the material, which facilitates 
proper opening and closing of the package, thus 
guaranteeing the initial manufacturing conditions 
of the finished product.
During the first week of the semi-field bioassay, 
all of the tested doses (0.13, 0.40, 0.66 and 0.93 
mg/L) of Bti-CECIF tablets (5,240 ITU/mg, active 
ingredient (a.i.): 1.33%) exhibited an efficacy of 
100% for larval mortality. Regarding residual activ-
ity of Bti-CECIF tablets, the highest dose used in 
our study was enough to keep an 80% mortality 
rate for up to two weeks. 
These results are in agreement with those reported 
by two studies in Brazil under semi-field conditions 
using Bti tablets VectoBacT™ (2,200 ITU/mg, a.i.: 
37.4%). In one of these studies, doses of 3.5 and 
7 mg/L were tested and it was found that a 100% 
A. aegypti larval mortality rate lasted up to two 
and three weeks, respectively (31). In the study by 
Zequi, et al. (32), VectoBacT™ tablets used at a 
0.9 mg/L dose caused 100% mortality in instar IV 
A. aegypti larvae during the first eight days, and 
on day 15 the mortality rate was 98.8%. In another 
study, Melo-Santos, et al. (33), obtained a greater 
residual activity using Bti tablets (1,146 ± 2 ITU/
mg, dose: one tablet/10 L, a.i. not reported) than 
in the above mentioned studies resulting in an A. 
aegypti larval mortality rate above 90% on days 
13 through 35 for containers exposed to sunlight 
and on days 40 through 54 for containers protected 
from sunlight.
Several studies in different countries using com-
mercially available and experimental Bti formula-
tions under semi-field conditions, with and without 
Figure 4. Logistic regression model for effectiveness (% RLD≥80) 
of Bti-CECIF tablets (dose 0.93 mg/L) as a function of the 
number of post-treatment days in tanks infested with Aedes 
aegypti. Gray lines represent 95% confidence intervals.
Figure 5. Post-treatment estimated concentrations of Bti in 
water tanks, bioassay field in San Carlos, Córdoba
Each line corresponds to a tank.
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water replacement and under sunlight exposure or 
shade, have shown that Bti residual activity does 
not last longer than one month (31-40). This low Bti 
residual activity, especially in those bioassays using 
tablets and no water exchange, may be partly due 
to the excipient serving as food source for larvae. 
Treteau, et al. (41), reported that Bti residual 
activity was inversely proportional to organic matter 
content because membrane receptors in the A. 
aegypti larvae intestinal epithelium were covered 
by the ingested particles, thus interfering with Bti 
binding (42).
In Colombia, a previous study tested Bti tablets 
under semi-field conditions (36) and analyzed 
containers exposed to sunlight. In that study, con-
trary to most other studies, a residual activity of 12 
weeks with larval mortality >80% was observed. 
Several studies conducted under field conditions 
in different countries with commercially available 
and experimental Bti tablets have shown that their 
residual activity is less than a month (25,37,43-46). 
In Colombia, several Bti formulations tested under 
field conditions (18,24,43,47) have yielded varied 
results depending on the study site. 
In our study, the use of Bti-CECIF tablets dosed 
at 0.93 mg/L under field conditions in water tanks 
in the two selected neighborhoods of San Carlos, 
Córdoba, showed that on day 7, 90% of the tanks 
exhibited an 80% A. aegypti larvae mortality. These 
results are in agreement with Suárez, et al. (18), 
study in which by testing two product presentations 
(liquid and granular) in different types of tanks 
the authors showed that the Bti residual activity 
extended for seven to nine days. The study by 
Kroeger, et al. (43), evaluated commercially avail-
able Bti tablets (Culinex™, 33,000 ITU/mg, and 
8,000 ITU/mg, no a.i. reported) which yielded, at 
the highest tested dose, a residual activity of 28 
days in which larvae mortality was >90%.
Our results under semi-field conditions were 
different from under field conditions. Although 
semi-field bioassays are considered to be a useful 
method for the selection of new insecticides and/
or doses to be applied under field conditions, 
they lack the ability to predict products real 
performance (25). This may be partly explained 
by several factors that may affect Bti products 
performance including environmental conditions 
such as water temperature, larval density, sunlight, 
and the association with filter feeders. Moreover, 
water exchange and uncontrolled water tank condi-
tions, such as those present under field conditions, 
contribute to turning them into potential breeding 
sites and may also have a negative effect on Bti 
efficacy (35,37,48).
Following WHO recommendations (20), we sur-
veyed community acceptance of our product as 
well as its relationship to vector control and related 
diseases. While the majority of the participants 
knew that A. aegypti is the vector for dengue and 
chikungunya viruses and that it breeds in water 
tanks, this knowledge is insufficient for successful 
mosquito control and disease prevention, as there 
is no direct relationship to their daily lives (43). 
Community acceptance of Bti-CECIF tablets was 
high since, on the one hand, they were aware of 
their effect on the A. aegypti larvae (information 
and periodic inspections), and on the other hand, 
the tablets did not affect water odor or appearance 
judged by the color (observation of the researchers). 
Altogether, our data showed that the Bti-CECIF 
tablets designed and developed at our institution 
exhibited larvicidal properties comparable to other 
commercial products since no significant differ-
ences with VectoBac 200G™ (2,200 ITU/mg, 0.5% 
a.i.) were identified. In addition, Bti-CECIF tablets 
are easier to use, since the user is only required to 
count the necessary tablets to treat a given water 
volume, and there is no need of weighing the product 
before adding it to the water (39,43). Furthermore, 
the tablet has the advantage of sinking to the bottom 
of the tanks, where A. aegypti larvae are usually 
found, as compared to granular formulations that 
remain floating on the water surface for several days. 
Given that these tablets have selective toxicity, they 
are odorless and tasteless once diluted in water. 
These features make them an attractive option for 
the final user as they do not generate a negative 
perception of the water (appearance of dirty water) 
(25). The community acceptance was evidenced 
in the survey administered to adult inhabitants of 
participating households.
The Pan American Health Organization (PAHO) 
and WHO proposed an integrated management 
strategy for the prevention and control or arbo-
viral diseases in endemic countries that includes 
six components (epidemiology, integrated vector 
management, social communication, patient care, 
laboratory, and environment) (49). Within the 
integrated vector management component, Bti-
CECIF tablets could be useful for those endemic 
areas where A. aegypti populations are resistant 
to temephos and water for human consumption is 
stored for later use. Moreover, Bti-CECIF tablets 
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should be used in conjunction with other control 
strategies including the elimination of breeding 
sites by members of the community and space 
fumigation by health authorities when required. In 
addition, such control strategy must be integrated 
into the social communication component in order 
to achieve community acceptance and participation 
in its application.
One of the limitations of Bti-CECIF tablets identified 
in our field studies was the low residual activity of the 
Bti since product reapplication was required. How-
ever, this could be addressed in future experiments 
by including new dosing schemes, or by performing 
additional fieldwork in other regions in order to 
analyze and identify trends in product performance.
In Colombia, there are currently no bioinsecticide 
manufacturing facilities meeting good manufac-
turing practices (GMP) standards. Therefore, our 
group is currently developing a project to design 
and build GMP facilities for the production of Bti-
CECIF tablets as it is technically and economi-
cally feasible.
In conclusion, our results strongly suggest that Bti-
CECIF tablets have a larvicidal effect on A. aegypti, 
the known vector for dengue, chikungunya, and 
Zika arboviruses. Given the high rate of infection 
of these arboviruses in Colombia, successful and 
affordable vector control strategies, such as our 
Bti-CECIF tablets, are of pivotal importance to pro-
vide better public health care.
Acknowledgements
The authors would like to thank Dr. Catalina 
Alfonso-Parra and Dr. Marcos Restrepo-Isaza for 
their scientific advice; Dr. Guillermo Rúa for the 
supply of A. aegypti eggs; Gaviota Lopera, Diana 
Cabarcas, Elkin Monterrosa, and John Edison 
Bedoya for their technical support, and especially 
the members of the communities of El Carmen and 
Porvenir in San Carlos, Córdoba. 
Financing
This work received the financial support of the 
Sistema Nacional de Ciencia y Tecnología, 
Colciencias, grant No. 381-2015, and of CECIF 
and ICMT-Universidad CES.
Conflicts of interest
The authors have no conflicts of interest to declare. 
References
1.  Musgrove P, Creese A, Preker A, Baeza C, Anell A, 
Prentice T. Health Systems: Improving perfomance. 
Geneva: World Health Organization; 2000. 
2.  Gürtler RE, Garelli FM, Coto HD. Effects of a five-year 
citywide intervention program to control Aedes aegypti and 
prevent dengue outbreaks in northern Argentina. PLoS 
Negl Trop Dis. 2009;3:e427. https://doi.org//10.1371/journal.
pntd.000042 
3.  Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow 
AW, Moyes CL, et al. The global distribution and burden of 
dengue. Nature. 2013;496:504-7. https://doi.org//10.1038/
nature12060
4.  Organización Panamerica de la Salud/Organización 
Mundial de la Salud. Casos reportados de dengue en las 
Américas, 2017. Accessed: March 5, 2018. Available from: 
http://www.paho.org/data/index.php/es/temas/indicadores-
dengue/dengue-nacional/9-dengue-pais-ano.html
5.  Instituto Nacional de Salud de Colombia. Informe del 
evento dengue, Colombia, 2013. Accessed: March 5, 2018. 
Available from: http://www.ins.gov.co/buscador-eventos/
Informesdeevento/Dengue 2013.pdf
6.  Instituto Nacional de Salud. Informe del evento dengue, 
Colombia, 2014. Accessed: March 5, 2018. Available from: 
http://www.ins.gov.co/buscador-eventos/Informesdeevento/
Dengue 2014.pdf
7.  Instituto Nacional de Salud. Informe del evento dengue, 
Colombia, 2015. Accessed: March 5, 2018. Available from: 
http://www.ins.gov.co/buscador-eventos/Informesdeevento/
Dengue 2015.pdf
8.  Instituto Nacional de Salud. Informe del evento de dengue, 
Colombia, 2016. Accessed: March 5, 2018. Available from: 
http://www.ins.gov.co/buscador-eventos/Informesdeevento/
Dengue 2016.pdf
9.  Instituto Nacional de Salud. Informe del evento dengue, 
Colombia, 2017. Accessed: March 5, 2018. Available from: 
http://www.ins.gov.co/buscador-eventos/Informesdeevento/
DENGUE PE XIII 2017.pdf
10.  Instituto Nacional de Salud. Informe del evento chikun-
gunya, Colombia, 2015. Accessed: March 5, 2018. Available 
from: http://www.ins.gov.co/lineas-de-accion/Subdireccion-
Vigilancia/Informe de Evento Epidemiolgico/CHIKUNGUNYA 
Periodo XIII 2015.pdf
11.  Instituto Nacional de Salud. Informe del evento chikun-
gunya, Colombia, 2016. Accessed: March 5, 2018. 
Available from: http://www.ins.gov.co/buscador-eventos/
Informesdeevento/Chikunguña 2016.pdf
12.  Instituto Nacional de Salud. Informe del evento Zika, 
Colombia - semanas epidemiológicas 32 de 2015 a 52 de 
2016. Accessed: March 5, 2018. Available from: http://www.
ins.gov.co/Noticias/ZIKA/Casos zika por municipio semana 
52 2016.pdf
13.  World Health Organization. Dengue, 2018. Accessed: March 
5, 2018. Available from: http://www.who.int/mediacentre/
factsheets/fs117/es/
14.  Organización Panamerica de la Salud/Organización 
Mundial de la Salud. Resolución CD55.R6: Estrategia para 
la prevención y control de las enfermedades arbovirales, 
2016. Accessed: March 5, 2018. Available from: https://www.
paho.org/hq/index.php?option=com_docman&task=doc
15.  Becker N, Zgomba M, Ludwig M, Petric D, Rettich F. 
Factors influencing the activity of Bacillus thuringiensis var. 
israelensis treatments. J Am Mosq Control Assoc. 1992;8: 
285-9. 
104
Biomédica 2018;38:95-105Gómez-Vargas W, Valencia-Jiménez K, Correa-Londoño G, et al.
16.  De Barjac H. Étude cytologique de l’action de Bacillus 
thuringiensis var. israelensis sur larves de moustiques. 
Comptes Rendus de l’Académie des Sci. 1978;286:1629-32. 
17.  Ponce G. Efecto de concentraciones subletales de Bacillus 
thuringiensis israelensis H-14 Vectobac AS® en parámetros 
biológicos de Ae. aegypti (tesis). San Nicolás de los Garza, 
N.L., México: Universidad Autónoma de Nuevo León; 1999. 
18.  Suárez M, Ayala W, Nelson M. Evaluacion de dos formu-
laciones de Bacillus thuringiensis H-14 para el control de 
larvas de Aedes aegypti. Biomédica. 1987;7:5-12. https://
doi.org/10.7705/biomedica.v7i1-2.1928 
19.  Gerberg E. Manual for mosquito rearing and experimental 
techniques. Am Mosq Control Assoc. 1970;5:1-9. 
20.  World Health Organization. Guidelines for laboratory and 
field testing of mosquito larvicides. Geneva: WHO; 2005. 
21.  Cadavid JM. Estructura genética microgeográfica y sus-
ceptibilidad a insecticidas de Aedes aegypti de Medellín. 
Medellín: Universidad de Antioquia; 2016. p. 79. 
22.  Departamento Administrativo Nacional de Estadística. 
Documento: Esquema de Ordenamiento Territorial. Muni-
cipio de San Carlos, Córdoba: DANE; 2005. 
23.  Mulla MS, Norland LR, Fanara DM, Darwazeh HA, 
McKean DW. Control of chironomid midges in recreational 
lakes. J Econ Entomol. 1971;64:300-7. 
24.  Ocampo CB, González C, Morales CA, Pérez M, Wesson 
D, Apperson CS. Evaluation of community-based strategies 
for Aedes aegypti control inside houses. Biomédica. 2009;29: 
282-97. https://doi.org//S0120-41572009000200020 
25.  Marcombe S, Darriet F, Agnew P, Etienne M, Yp-Tcha MM, 
Yébakima A, et al. Field efficacy of new larvicide products 
for control of multi-resistant Aedes aegypti populations 
in Martinique (French West Indies). Am J Trop Med Hyg. 
2011;84:118-26. 
26.  World Health Organization. Bacillus thuringiensis israelensis 
(Bti) in drinking-water. Geneva: World Health Organization; 
2009. p. 8. 
27.  Instituto Nacional de Salud. Informe epidemiológico: Red 
de vigilancia de la resistencia a insecticidas de uso en salud 
pública en Colombia 2004-2014. Bogotá: Instituto Nacional 
de Salud; 2014. p. 27. 
28.  Maestre R, Rey G, de las Salas J, Vergara C, Santacoloma 
L, Goenaga S, et al. Estado de la susceptibilidad de Aedes 
aegypti a insecticidas en Atlántico (Colombia). Rev Colomb 
Entomol. 2010;36:242-8. 
29.  Conde M, Orjuela LI, Castellanos CA, Herrera-Varela M, 
Licastro S, Quiñones ML. Evaluación de la sensibilidad 
a insecticidas en poblaciones de Aedes aegypti (Diptera: 
Culicidae) del departamento de Caldas, Colombia, en 2007 
y 2011. Biomédica. 2014;35:43-52. https://doi.org//10.7705/
biomedica.v35i1.23 
30.  Maestre R, Rey G, de las Salas J, Vergara C, Santacoloma 
L, Goenaga S, et al. Susceptibilidad de Aedes aegypti 
(Diptera: Culicidae) a temefos en Atlántico-Colombia. Rev 
Colomb Entomol. 2009;35:202-5. 
31.  Vilarinhos P, Monnerat R. Larvicidal persistence of 
formulations of Bacillus thuringiensis var. israelensis to 
control larval Aedes aegypti. J Am Mosq Control Assoc. 
2004;20:311-4. 
32.  Zequi JAC, Lopes J, Santos FP. Efficacy and persistence 
of two Bacillus thuringiensis israelensis formulations for the 
control of Aedes aegypti (Linnaeus, 1762) under simulated 
field conditions. Int J Mosq Res. 2015;2:5-9. 
33.  Melo-Santos MAV de, Gomes Sanchez E, de Jesus FJ, 
Regis L. Evaluation of a new tablet formulation based on 
Bacillus thuringiensis sorovar. israelensis for larvicidal 
control of Aedes aegypti. Mem Inst Oswaldo Cruz. 2001; 
96:859-60. 
34.  Boyce R, Lenhart A, Kroeger A, Velayudhan R, Roberts 
B, Horstick O. Bacillus thuringiensis israelensis (Bti) for the 
control of dengue vectors: Systematic literature review. Trop 
Med Int Heal. 2013;18:564-577. https://doi.org//10.1111/
tmi.12087 
35.  Becker N, Djakaria S, Kaiser A, Zulhasril O, Ludwig HW. 
Efficacy of a new tablet formulation of an asporogenous 
strain of Bacillus thuringiensis israelensis against larvae of 
Aedes aegypti. Bull Soc Vector Ecol. 1991;16:176-82. 
36.  Armengol G, Hernández J, Vélez JG, Orduz S. Long-
lasting effects of a Bacillus thuringiensis serovar israelensis 
experimental tablet formulation for Aedes aegypti (Diptera: 
Culicidae) control. J Econ Entomol. 2006;99:1590-1595. 
https://doi.org//10.1093/jee/99.5.1590
37.  Mahilum MM, Ludwig M, Madon MB, Becker N. Evalua-
tion of the present dengue situation and control strategies 
against Aedes aegypti in Cebu City, Philippines. J vector 
Ecol. 2005;30:277-83. 
38.  Mulla MS, Thavara U, Tawatsin A, Chompoosri J. 
Procedures for evaluation of field efficacy of slow-release 
formulations of larvicides against Aedes aegypti in water-
storage containers. J Am Mosq Control Assoc. 2004;20: 
64-73. 
39.  Benjamin S, Rath A, Chiang YF, Lee HL. Efficacy of 
a Bacillus thuringiensis israelensis tablet formulation, 
VectoBac DT®, for control of dengue mosquito vectors 
in potable water containers. Southeast Asian J Trop Med 
Public Health. 2005;36:879-92. 
40.  Monnerat R, Dumas V, Ramos F, Pimentel L, Nunes A, 
Sujii E, et al. Evaluation of different larvicides for the con-
trol of Aedes aegypti (Linnaeus) (Diptera: Culicidae) under 
simulated field conditions. BioAssay. 2012;7:1-4. 
41.  Tetreau G, Stalinski R, Kersusan D, Veyrenc S, David JP, 
Reynaud S, et al. Decreased toxicity of Bacillus thuringiensis 
subsp. israelensis to mosquito larvae after contact with leaf 
litter. Appl Environ Microbiol. 2012;78:5189-95. https://doi.
org//10.1128/AEM.00903-12 
42.  Ben-Dov E, Saxena D, Wang Q, Manasherob R, Boussiba 
S, Zaritsky A. Ingested particles reduce susceptibility of 
insect larvae to Bacillus thuringiensis. J Appl Entomol. 2003; 
127:146-52. https://doi.org//10.1046/j.1439–0418.2003 
43.  Kroeger A, Dehlinger U, Burkhardt G, Atehortua W, 
Anaya H, Becker N. Community based dengue control 
in Columbia: People’s knowledge and practice and the 
potential contribution of the biological larvicide Bti (Bacillus 
thuringiensis israelensis). Trop Med Parasitol. 1995;46: 
241-6. 
44.  Phan-Urai P, Kong-ngamsuk W, Malainual N. Field trial 
of Bacillus thuringiensis H-14 (Larvitab®) against Aedes 
aegypti larvae in Amphoe Khlung, Chanthaburi Province, 
Thailand. J Trop Med Parasitol. 1995;18:106-14. 
105
Biomédica 2018;38:95-105 Bti-CECIF larvicidal tablets for Aedes aegypti
45.  Batra CP, Mittal PK, Adak T. Control of Aedes aegypti 
breeding in desert coolers and tires by use of Bacillus 
thuringiensis var. israelensis formulation. J Am Mosq 
Control Assoc. 2000;16:321-3. 
46.  Setha T, Chantha N, Socheat D, Benjamin S. Efficacy of 
VectoBac WG, a Bacillus thuringiensis israelensis formula-
tion, to control dengue mosquito vectors in Cambodia. Am J 
Trop Med Hyg. 2007;77:256-7. 
47.  Ortegón-Cárdenas L, Carvajal-López D. Efectividad del 
Bacillus thuringiensis israelensis como control biológico 
para larvas de Aedes aegypti en Florencia (Caquetá, 
Colombia). Momentos Cienc. 2009;6:100-4. 
48.  Ponce G, Flores AE, Badii MH, Fernández I, Rodríguez 
ML. Evaluación de Bacillus thuringiensis isaraelensis 
(VectoBac 12 ASâ ) sobre la población larval de Aedes 
aegypti en el área metropolitana de Monterrey N. L. México. 
Rev la Fac Salud Pública y Nutr Univ Autónoma León. 
2003;4:3-9. 
49.  Organización Panamericana de la Salud/Organización 
Mundial de la Salud. La estrategia de gestión integrada 
para la prevención y el control del dengue en la Región de 
las Américas. Washington, D.C.: OPS/OMS; 2017. p. 70. 
